JPRN-UMIN000017010已完成2 期
Weekly nab-PTX in Combination with Gemcitabine in Patients with Non-Small-Cell Lung Cancer Previously Treated with Platinum based Chemotherapy - Weekly nab-PTX in Combination with Gemcitabine in Lung Cancer patient Previously Treated with Platinum based Chemotherapy
Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine0 个研究点目标入组 28 人开始时间: 2015年4月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
The overall response rate was 17.9%. The disease control rate was 67.9%. The median progression-free survival was 3.1 months. Adverse events were generally tolerable except grade 3 interstitial pneumonia with in 4 patients.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)interstitial pneumonia or pulmonary fibrosis detectable on CT scan 2)history of drug induced interstitial pneumonia 3)history of severe drug allergy 4)patients previously treated with paclitaxel, gembcitabine, nab-paclitaxel. 5)history of active infection or other serious disease condition 6)history of poorly controlled pleural effusion,pericardial effusion and ascites 7)history of severe heart disease(uncontrollable arrythmia,uncontrollable angina pectoris,heart failure, etc.) 8)uncontrollable diabetes mellitus 9)curative radiotherapy pretreated to the chest. 10)current neuropathy >Grade2 11)history of active double cancer 12)history of active psychological disease 13)history of pregnancy or lactation 14)any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
研究者
相似试验
已完成
2 期
Bevacizumab (Avastin) therapy in combination with carboplatin and weekly paclitaxel for advanced non-squamous non-small cell lung canceron-squamous Non-small-cell Lung CancerJPRN-UMIN000003566Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital33
已完成
2 期
Phase II study of gemcitabine plus oxaliplatin combination therapy (GEMOX therapy) for the advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or with a personal history of breast/ovarian/prostate cancer.Metastatic pancreatic cancer patients with a family history of pancreatic/breast/ovarian/prostate cancer or with a personal history of breast/ovarian/prostate cancer.JPRN-UMIN000017894ational Cancer Center Hospital45
已完成
2 期
Phase 2 study of imatinib-combined chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia (JALSG Ph+ALL202)Acute lymphoblastic leukemiaJPRN-C000000065Japan Adult Leukemia Study Group100
已完成
不适用
Clinical factor for clinicians to choose treatments to refractory ulcerative colitis patients, and the validity of the treatment.JPRN-UMIN000025277agasaki university graduate school of Biomedecal Science Department of Gastroenterology and hepatology150
已完成
不适用
A phase II study of S-1 therapy for advanced/recurrent esophageal cancer resistant/intolerable to 5-FU, Platinum compounds, and Taxane (OGSG1404)Esophageal carcinomaJPRN-UMIN000016830Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)17